UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4548-4554

2011

Volltextzugriff (PDF)

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Clinical cancer research, 2012-04, Vol.18 (8), p.2316-2325

2012

Volltextzugriff (PDF)

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors

Clinical cancer research, 2014-10, Vol.20 (19), p.5032-5040

2014

Volltextzugriff (PDF)

Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2551-2551

2021

Volltextzugriff (PDF)

Abstract 1137: Determination of a recommended Phase 2 dose (RP2D) for SRF388, a first-in-class IL-27-blocking antibody, in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1137-1137

2022

Volltextzugriff (PDF)

Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.278-278

2015

Volltextzugriff (PDF)

Routine molecular profiling of solid tumors in a community cancer center's genomic pathology laboratory

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e22088-e22088

2013

Volltextzugriff (PDF)

The effect of tivantinib on QTc interval in subjects with advanced solid tumors and healthy subjects

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e13528-e13528

2014

Volltextzugriff (PDF)

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.220-220

2014

Volltextzugriff (PDF)

Phase I development of a weekly dosing schedule for the oral taxane tesetaxel

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2555-2555

2012

Volltextzugriff (PDF)

Treatment of advanced ovarian and endometrial cancer in the phase I setting: A single center experience

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e13509-e13509

2014

Volltextzugriff (PDF)

Personalizing cancer treatment of combined targeting of PI3K/AKT and MAPK pathways in advanced cancer patients harboring simultaneous oncogenic alterations in both signaling pathways

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13025-e13025

2012

Volltextzugriff (PDF)

Abstract B17: Establishment, characterization and evaluation of a panel of patient-derived colorectal tumor models

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B17-B17

2011

Volltextzugriff (PDF)

Abstract B125: Identification and characterization of a panel of B-Raf wildtype and mutant patient-derived low passage tumor models

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.B125-B125

2011

Volltextzugriff (PDF)

MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13602-e13602

2012

Volltextzugriff (PDF)

MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13604-e13604

2012

Volltextzugriff (PDF)

Abstract 4179: Promising clinical activity of a NAB paclitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer

Cancer research (Chicago, Ill.), 2008-05, Vol.68 (9_Supplement), p.4179-4179

2008

Volltextzugriff (PDF)

Phase I and pharmacokinetic trial of weekly CPT-11

Journal of clinical oncology, 1993-11, Vol.11 (11), p.2194-2204

1993

Volltextzugriff (PDF)

A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies

Cancer research (Chicago, Ill.), 1993-12, Vol.53 (24), p.5929-5933

1993

Volltextzugriff (PDF)

A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors

Cancer chemotherapy and pharmacology, 1995-01, Vol.35 (5), p.397-402

1995

Volltextzugriff (PDF)

Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology

PLoS medicine, 2007-12, Vol.4 (12), p.e352

2007

Volltextzugriff (PDF)

Artemisinin Resistance in Cambodia: A Clinical Trial Designed to Address an Emerging Problem in Southeast Asia

Clinical infectious diseases, 2010-12, Vol.51 (11), p.e82-e89

2010

Volltextzugriff (PDF)

Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria

Alzheimer's & dementia, 2022-04, Vol.18 (4), p.810-823

2022

Volltextzugriff (PDF)

Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs

Journal of the American Association for Laboratory Animal Science, 2020-11, Vol.59 (6), p.737-741

2020

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(174)

Publikationsform

Sprache

Englisch
(192)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(112)
Humans
(108)
Male
(71)
Female
(70)
Biological And Medical Sciences
(53)
Medical Sciences
(46)
Aged
(44)
Middle Aged
(43)
Adult
(40)
Oncology
(27)
Risk Factors
(22)
Genetics & Heredity
(20)
Aged, 80 And Over
(19)
Pharmacology. Drug Treatments
(19)
Polymorphism, Single Nucleotide
(19)
Genetic Predisposition To Disease
(18)
Multidisciplinary Sciences
(18)
Science & Technology - Other Topics
(18)
Neoplasms - Drug Therapy
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors

Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors

Abstract 1137: Determination of a recommended Phase 2 dose (RP2D) for SRF388, a first-in-class IL-27-blocking antibody, in patients with advanced solid tumors

Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)

Routine molecular profiling of solid tumors in a community cancer center's genomic pathology laboratory

The effect of tivantinib on QTc interval in subjects with advanced solid tumors and healthy subjects

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)

Phase I development of a weekly dosing schedule for the oral taxane tesetaxel

Treatment of advanced ovarian and endometrial cancer in the phase I setting: A single center experience

Personalizing cancer treatment of combined targeting of PI3K/AKT and MAPK pathways in advanced cancer patients harboring simultaneous oncogenic alterations in both signaling pathways

Abstract B17: Establishment, characterization and evaluation of a panel of patient-derived colorectal tumor models

Abstract B125: Identification and characterization of a panel of B-Raf wildtype and mutant patient-derived low passage tumor models

MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors

MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel

Abstract 4179: Promising clinical activity of a NAB paclitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer

Phase I and pharmacokinetic trial of weekly CPT-11

A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies

A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors

Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology

Artemisinin Resistance in Cambodia: A Clinical Trial Designed to Address an Emerging Problem in Southeast Asia

Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria

Pharmacokinetics of Sustained-release, Oral, and Subcutaneous Meloxicam over 72 Hours in Male Beagle Dogs

Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future

Suchergebnisse filtern